Lantern Pharma Inc Total Liabilities
Lantern Pharma Inc total liabilities. Based on the latest financial reports, Lantern Pharma Inc (LTRN) has total liabilities worth $11.82 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lantern Pharma Inc (LTRN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lantern Pharma Inc (2018–2025)
Total liabilities of Lantern Pharma Inc from 2018 to 2025. This chart illustrates how Lantern Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Lantern Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Lantern Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RAREX Ltd
AU:REE
|
Australia | AU$771.55K |
|
Birks Group Inc
NYSE MKT:BGI
|
USA | $233.73 Million |
|
Talisman Mining Ltd
F:RJA
|
Germany | €1.46 Million |
|
Infimer Ltd
TA:INFR
|
Israel | ILA7.50 Million |
|
Orcoda Ltd
AU:ODA
|
Australia | AU$6.42 Million |
|
Fatfish Group Ltd
AU:FFG
|
Australia | AU$12.26 Million |
|
Imperial Pacific Ltd
AU:IPC
|
Australia | AU$1.81 Million |
|
Solo Brands, Inc.
NYSE:SBDS
|
USA | $316.38 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Lantern Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LTRN total asset value.
Liquidity & Leverage Metrics
Lantern Pharma Inc Total Liabilities Ratios Explained
Lantern Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lantern Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lantern Pharma Inc (2018–2025)
The table below shows the annual total liabilities of Lantern Pharma Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.50 Million | +2.68% |
| 2024-12-31 | $4.38 Million | +60.02% |
| 2023-12-31 | $2.74 Million | -2.09% |
| 2022-12-31 | $2.80 Million | +17.62% |
| 2021-12-31 | $2.38 Million | +260.01% |
| 2020-12-31 | $660.84K | +35.06% |
| 2019-12-31 | $489.29K | -24.91% |
| 2018-12-31 | $651.63K | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more